Metformin for the Treatment of Recurrent or Progressive Posterior Fossa Group A Ependymoma, PNOC041 Trial

Inclusion Criteria

• Participants must have recurrent or progressive posterior fossa A (PFA) ependymoma following surgery AND radiation treatment (RT)
• Participants must have a diagnosis of PFA ependymoma either at initial diagnosis or at recurrence. Any number of previous recurrences are permissible provided the participant meets other enrollment criteria
• Participants must have adequate tumor tissue available from initial diagnosis or from pre-trial enrollment. Formalin-fixed paraffin-embedded (FFPE) material (1 full block) should be provided. If FFPE material is not available, 10 unstained slides with an accompanying hematoxylin and eosin staining method (H & E) report should be provided
• TV PHASE: Participants are candidates to undergo elective surgery for removal of all or a portion of their recurrent/progressive tumor
• EFFICACY PHASE: Participant must have measurable disease; this will be defined as lesions that can be accurately measured in two dimensions (longest diameter to be recorded) The size threshold is met if both inplane diameters are ≥ 10 mm or both inplane diameters are at least two times the MRI slice thickness, plus the interslice gap with a minimum size of no less than double the slice thickness on MRI
• EFFICACY PHASE: Participants with an isolated local progression of the tumor following RT (or stereotactic radiosurgery, SRS) must be > 6 months from completion of RT to the lesion to rule out pseudo progression or must have tissue confirmation of progression prior to enrollment
• EFFICACY PHASE: Previously irradiated lesions are considered non-measurable except in cases of documented progression of the lesion since the completion of radiation therapy
• Participants must not be receiving metformin for other medical indications or previous exposure to metformin following their diagnosis of PFA ependymoma. However, participants treated on the TV phase, but did not continue onto maintenance therapy will be allowed to enroll on the efficacy phase with future recurrences or progression of their disease
• Age: 1-39 years at the time of enrollment
• Performance score: Karnofsky ≥ 50 for participants > 16 years of age and Lansky ≥ 50 for participants ≤ 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
• Participants who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration
• Peripheral absolute neutrophil count (ANC) ≥ 1000/mm^3
• Platelet count ≥ 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)
• A serum creatinine ≤ 1.5 upper limit normal (ULN) based on age and gender
• Total bilirubin ≤ 1.5 x ULN for age; in presence of Gilbert’s syndrome, total bilirubin ≤ 3 x ULN or direct bilirubin ≤ 1.5 x ULN
• Alanine aminotransferase (ALT) ≤ 3 x ULN
• Aspartate aminotransferase (AST) ≤ 3 x ULN
• Participants with seizure disorder may be enrolled if well controlled and are on stable dose of anti-seizure medication for > 72 hours prior to enrollment
• Subjects who have neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration
• Participants must enroll on Pediatric Neuro-Oncology Consortium Comprehensive Protocol (PNOC COMP) if PNOC COMP is open to accrual at the enrolling institution
• A legal parent/guardian or participant must be able to understand, and willing to sign, a written informed consent and assent document, as appropriate

Exclusion Criteria

• Participants with a history of diabetes mellitus or those found to have pre-diabetes on hemoglobin A1C (HbA1C) screening test are excluded from the study
• Participants without any measurable disease but with only isolated leptomeningeal disease progression
• Participants who have had chemotherapy or have received radiotherapy to the non-target lesion within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
• Participants must be at least 7 days since the completion of therapy with a biologic or small molecule agent. For any agent with known adverse events that can occur beyond 7 days after administration, the period prior to enrollment must be beyond the time during which adverse events are known to occur. Such participants should also be discussed with study chairs
• Participants with rapidly progressive symptoms that require urgent surgery that in the investigators assessment cannot be safely deferred for 6 weeks are excluded from target validation phase of the study
• Participants who are receiving any other investigational agents
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection
• Women of childbearing potential must not be pregnant or breast-feeding
• Human immunodeficiency virus- (HIV) positive participants will be ineligible if HIV therapy regimen has not been stable for at least 4 weeks or there is intent to change the regimen within 8 weeks following enrollment, or if they are severely immunocompromised